Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the local directory fallback.
Local D1 index available.
Filters: Condition: Juvenile Idiopathic Arthritis Clear all
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
Abatacept, TNFi (Tumor Necrosis Factor inhibitor) medication, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 18, 2026, 4:48 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Fibromyalgia, Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus
Interventions
No Intervention
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
5 Years to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 20, 2026, 2:14 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
1 Year to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Valhalla, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 18, 2026, 1:02 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Congenital Bone Marrow Failure Syndromes, Hereditary Anemias, Inflammatory Conditions, Inherited Metabolic Disorders (IMD), Juvenile Rheumatoid Arthritis (JRA), Primary Immunodeficiency (PID), Systemic Juvenile Idiopathic Arthritis (sJIA)
Interventions
Alemtuzumab, Fludarabine, Hydroxyurea, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 20, 2026, 11:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Anterior Uveitis (AU), Behcet Disease, Birdshot Chorioretinitis, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Posterior Vitreous Detachment, Sarcoidosis, Spondyloarthritis (SA)
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced May 20, 2026, 8:43 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 12, 2026, 4:00 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced May 19, 2026, 7:28 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Joint Hypermobility, Juvenile Dermatomyositis, Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood
Interventions
FIT Teens
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced May 18, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Juvenile Dermatomyositis (JDM), Juvenile Idiopathic Arthritis (JIA), Multiple Sclerosis (MS), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Pemphigus Vulgaris, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Interventions
Ad26.COV2.S, BNT162b2, BNT162b2, Bivalent, Continue IS (B cell depletion therapy), Continue IS (MMF or MPA), Continue IS (MTX), Moderna mRNA-1273, Moderna mRNA-1273, Bivalent, Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (B cell depletion therapy), Withhold IS (MMF or MPA), Withhold IS (MTX)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 20, 2026, 8:43 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
JIA, Juvenile Idiopathic Arthritis
Interventions
Methotrexate, adalimumab
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
849 participants
Timeline
2008 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Apr 22, 2026, 11:21 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Alopecia, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ankylosing Spondylitis, Arrythmia, Asthma, Ataxia, Axial Spondyloarthritis, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Chronic Inflammation, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease, Cluster Headache, Congenital Heart Disease, Crohn Disease, Cystic Fibrosis, Dermatomyositis, Diabetes, Diffuse Idiopathic Skeletal Hyperostosis, Eczema, Epilepsy, Fibromyalgia, Giant Cell Arteritis, Gout, Guillain-Barre Syndrome, Head Injury, Headache, Heart Attack, Heart Failure, High Blood Pressure, Hydrocephalus, Inflammatory Bowel Diseases, Juvenile Idiopathic Arthritis, Lumbar Disc Disease, Lung Cancer, Lupus Erythematosus, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Myositis, Neurocutaneous Syndromes, Obesity, Osteoarthritis, Osteoporosis, Parkinson Disease, Peripheral Arterial Disease, Polymyalgia Rheumatica, Polymyositis, Psoriasis, Psoriatic Arthritis, Relapsing Polychondritis, Rheumatoid Arthritis, Scleroderma, Sleep Apnea, Spinal Cord Injuries, Stroke, Temporal Arteritis, Tension-Type Headache, Undifferentiated Connective Tissue Disease, Unstable Angina, Valve Heart Disease, Wegener
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 20, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Active Polyarticular Juvenile Idiopathic Arthritis
Interventions
Abatacept
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Apr 29, 2026, 8:41 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced May 4, 2026, 11:42 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced May 19, 2026, 6:22 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Apr 29, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Ankylosing Spondylitis, Crohn Disease, Hidradenitis Suppurativa, Non-infectious Uveitis, Pediatric Crohns Disease, Pediatric Plaque Psoriasis, Plaque Psoriasis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced May 20, 2026, 10:02 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 19 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced May 12, 2026, 12:16 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Omaha, Nebraska • Cleveland, Ohio • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced May 6, 2026, 8:42 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced May 5, 2026, 1:20 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Withdrawal of anti-TNF therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Apr 29, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CNTO 148 (Golimumab), Methotrexate, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 18 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced May 14, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions
methotrexate, methotrexate - etanercept - prednisolone arm
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced May 20, 2026, 1:19 PM EDT